Using motivational interviewing and mindfulness to help reduce substance use
Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for Tobacco Dependence and Other Drug Use in Methadone Treatment
This study is testing whether combining motivational interviewing and mindfulness techniques can help people who struggle with using multiple substances, like opioids and tobacco, to reduce their use.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 420 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rutgers, The State University of New Jersey Academic / other |
| Locations | 2 sites (New Brunswick, New Jersey and 1 other locations) |
| Trial ID | NCT06033599 on ClinicalTrials.gov |
What this trial studies
This study aims to explore the implementation of Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for individuals struggling with polysubstance abuse, particularly focusing on opioid and tobacco use. It will assess barriers and facilitators to the adoption of these interventions in clinical settings while also evaluating their effectiveness in reducing substance use among participants. The study will involve various treatment groups, including those receiving MI and MORE, as well as support groups, to determine the best approach for patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are English-speaking adults aged 18 and older who are currently on methadone and smoke cigarettes.
Not a fit: Patients with severe cognitive impairment, psychosis, or those who are currently pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide effective strategies for reducing substance use and improving recovery outcomes for individuals with polysubstance abuse issues.
How similar studies have performed: Other studies have shown promise in using motivational interviewing and mindfulness techniques for substance use treatment, indicating that this approach has potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * English-speaking * Age ≥18 * Currently on methadone; and 4) currently smoke cigarettes. Exclusion Criteria: * Severe cognitive impairment (score \>23 on Mini Mental Status Exam) or psychosis (positive SCID Psychotic Screen) * Suicidal risk (score ≥7 on Suicidal Behaviors Questionnaire) * Inability to attend or fully participate in intervention sessions or assessments * Previous formal mindfulness training (e.g., MBSR, MBRP) or MORE (from the R21 or R33 * Currently taking smoking cessation pharmacotherapy or participating in smoking cessation counseling * Any contraindications for NRT * Currently or soon planning to be pregnant or breastfeeding.
Where this trial is running
New Brunswick, New Jersey and 1 other locations
- Rutgers Robert Wood Johnson Medical School — New Brunswick, New Jersey, United States (Recruiting)
- University of Utah — Salt Lake City, Utah, United States (Recruiting)
Study contacts
- Principal investigator: Nina Cooperman, PsyD — Rutgers Robert Wood Johnson Medical School
- Study coordinator: Nina Cooperman, PsyD
- Email: cooperna@rwjms.rutgers.edu
- Phone: 732-235-8569
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.